Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist
Contact+90 (538) 677 60 18

Surgery for Mesothelioma: For Whom and When?

Surgery for Mesothelioma: For Whom and When?
In this article

A strong response from the Mount Sinai team to the perception created by MARS2 that surgery is harmful: surgical mortality (death rate) can fall as low as 0% in experienced centers and in the epithelioid subtype.

Surgery remains an option in mesothelioma: pleurectomy/decortication is safe and effective in the right patientPleural mesothelioma (cancer of the lining of the lungs) is an aggressive cancer associated with asbestos exposure and difficult to treat. In 2024, the THE LANCET Respiratory Medicine publication of the MARS2 studysparked a major debate in oncology by asserting that surgery (pleurectomy/decortication) caused patients more harm than chemotherapy and shortened survival. However, many experts argued that these results stemmed from inappropriate patient selection and surgical quality rather than surgery itself. This new study, published on February 2, 2026, demonstrates that surgery remains one of the most effective tools in the right hands and the right patient.

The Mount Sinai experience: a response to MARS2

Dr. Raja Flores and his team at Mount Sinai Hospital, one of the world's leading centers, published outcomes for patients operated on at their center during the same period as the MARS2 study (2015-2021).

The study included patients who underwent lung-sparing surgery known as pleurectomy/decortication (PD) , with 71 patients enrolled. More hazardous operations such as extrapleural pneumonectomy (complete removal of the lung together with its lining) were excluded in these patients.

Precision in patient selection

Patient selection criteria were emphasized as the key to success:

  • Histology Matters: 79% of patients had the epithelioid subtype, which responds best to surgery. (Only 2.8% had the sarcomatoid type.)
  • Comprehensive Staging: All patients (100%) underwent preoperative PET-CT and pulmonary function testing.

Results: a dramatic difference in safety

The high death rates observed in the surgical arm of MARS2 gave way to a safe outcome profile in this study.

90-Day Postoperative Mortality Rate
Mount Sinai Series (This Study)
%4.2
MARS2 Study (Surgical Arm)
9.0% (More Than Double)
30-Day Outcome: No Deaths In the Mount Sinai series, within the first 30 days after surgery (in-hospital mortality), no patients died (0%). This is the clearest indication of how safely mesothelioma surgery can be performed at experienced centers.
MARS2 Results: Lessons Learned from Modern-Day Outcomes of Surgery for Pleural Mesothelioma
DrÖzdoğan Academy Commentary

Surgery: Not for Everyone, but Essential for the Right Patient

Removing surgery entirely from the mesothelioma treatment equation means throwing the baby out with the bathwater. This study reminds us that surgical success depends not only on the surgeon's manual skills but also on knowing who should not undergo surgery .

If a patient's tumor is of the epithelioid type, their general condition is good, and the operation will be performed at an experienced, high-volume center, surgery remains the strongest option for long-term survival. However, in aggressive tumors such as the sarcomatoid type, or in inexperienced hands, surgery may do more harm than good. Treatment decisions must be individualized and made in multidisciplinary tumor boards.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Surgery for Mesothelioma: For Whom and When?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy